Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer.
Shen G, Cui W, Zhang H, Zhou F, Huang W, Liu Q, Yang Y, Li S, Bowman GR, Sadler JE, Gross ML, Li W.
Nat Struct Mol Biol. 2017 Jan;24(1):69-76. doi: 10.1038/nsmb.3333. Epub 2016 Dec 5.
Similar articles
Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling.
Lewis BC, Nair PC, Heran SS, Somogyi AA, Bowden JJ, Doogue MP, Miners JO.
Pharmacogenet Genomics. 2016 Jan;26(1):44-50. doi: 10.1097/FPC.0000000000000184.
Warfarin use and dose adjustment in a patient with mitral valve replacement.
Yuan SM.
Pak J Pharm Sci. 2015 Jul;28(4):1351-5.
Anticoagulant management of pregnant women with mechanical heart valve replacement during perioperative period.
Bian C, Qi X, Li L, Zhao J, Liu X.
Arch Gynecol Obstet. 2016 Jan;293(1):69-74. doi: 10.1007/s00404-015-3768-0. Epub 2015 Jun 6.
Warfarin resistance due to VKORC1 gene mutation in a patient following mechanical aortic valve replacement with an ON-X valve.
O' Sullivan KE, Meany B, Hurley JP.
Int J Cardiol. 2015 Jun 1;188:63-4. doi: 10.1016/j.ijcard.2015.04.045. Epub 2015 Apr 7. No abstract available.
Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.
de Oliveira Almeida VC, Ribeiro DD, Gomes KB, Godard AL.
Mol Diagn Ther. 2014 Dec;18(6):675-83. doi: 10.1007/s40291-014-0121-4.
VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
Azzam H, Elwakeel H, Awad I, El-Farahaty R, El-Gilany AH, El-Sharawy S.
Blood Coagul Fibrinolysis. 2016 Mar;27(2):121-6. doi: 10.1097/MBC.0000000000000168.
Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling.
Müller E, Keller A, Fregin A, Müller CR, Rost S.
BMC Genet. 2014 Feb 4;15:17. doi: 10.1186/1471-2156-15-17.
Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis.
Shearer MJ, Newman P.
J Lipid Res. 2014 Mar;55(3):345-62. doi: 10.1194/jlr.R045559. Epub 2014 Jan 31. Review.
The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations.
Sominsky S, Korostishevsky M, Kurnik D, Aklillu E, Cohen Y, Ken-Dror G, Loebstein R, Halkin H, Gak E.
J Appl Genet. 2014 May;55(2):163-71. doi: 10.1007/s13353-013-0189-2. Epub 2014 Jan 15.
Comparative genetics of warfarin resistance.
Oldenburg J, Müller CR, Rost S, Watzka M, Bevans CG.
Hamostaseologie. 2014;34(2):143-59. doi: 10.5482/HAMO-13-09-0047. Epub 2013 Nov 29. Review.
Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces.
Czogalla KJ, Biswas A, Wendeln AC, Westhofen P, Müller CR, Watzka M, Oldenburg J.
Blood. 2013 Oct 10;122(15):2743-50. doi: 10.1182/blood-2013-05-501692. Epub 2013 Aug 27.
C3435T polymorphism of MDR1 gene with warfarin resistance.
Kim Y, Smith A, Wu AH.
Clin Chim Acta. 2013 Oct 21;425:34-6. doi: 10.1016/j.cca.2013.07.010. Epub 2013 Jul 19.
Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
Di Fusco D, Ciccacci C, Rufini S, Forte V, Novelli G, Borgiani P.
Thromb Res. 2013 Jul;132(1):123-6. doi: 10.1016/j.thromres.2013.05.002. Epub 2013 May 30.
Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.
Tie JK, Jin DY, Tie K, Stafford DW.
J Thromb Haemost. 2013 Aug;11(8):1556-64. doi: 10.1111/jth.12306.
Possible warfarin resistance due to interaction with ascorbic acid: case report and literature review.
Sattar A, Willman JE, Kolluri R.
Am J Health Syst Pharm. 2013 May 1;70(9):782-6. doi: 10.2146/ajhp110704. Review.
A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.
Fregin A, Czogalla KJ, Gansler J, Rost S, Taverna M, Watzka M, Bevans CG, Müller CR, Oldenburg J.
J Thromb Haemost. 2013 May;11(5):872-80. doi: 10.1111/jth.12185.
Lipid solubility of warfarin may contribute to warfarin resistance in patients receiving total parenteral nutrition.
McAllister RK, Weinberg GL.
Am J Med Sci. 2012 Oct;344(4):340. No abstract available.
Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction.
Kurnik D, Qasim H, Sominsky S, Lubetsky A, Markovits N, Li C, Stein CM, Halkin H, Gak E, Loebstein R.
Thromb Haemost. 2012 Oct;108(4):781-8. Epub 2012 Aug 7.
The safety of cruciferous plants in humans: a systematic review.
Scott O, Galicia-Connolly E, Adams D, Surette S, Vohra S, Yager JY.
J Biomed Biotechnol. 2012;2012:503241. doi: 10.1155/2012/503241. Epub 2012 Feb 22. Review.
Filters: Manage Filters